Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus stereotactic radiotherapy in oligometastatic NSCLC
CTR20200434Phase 2Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in non-small cell lung cancer (NSCLC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started May 2020; status: terminated.
02
Drugs
benmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200434.